Home > Boards > US Listed > Medical - Drugs >

Kintara Therapeutics Inc. (KTRA)

KTRA RSS Feed
Add KTRA Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 7/7/2021 3:42:21 PM - Followers: 40 - Board type: Free - Posts Today: 0

Del Mar Pharmaceuticals


http://www.delmarpharma.com/



Del Mar Pharma is developing new drug candidates targeting orphan cancer indications representing market opportunities in the US$100s of millions in North America and potentially billions of dollars worldwide. We aim to develop products that will have a high impact in patient care and a high return for our investors.
In order to accelerate our development timelines and reduce technical risk, we leverage existing clinical and commercial data from a wide range of sources. This business model has been well validated and demonstrated to position for investor exit with significant upside, even prior to commercialization.
 

Key elements of our business strategy include:

  • Leveraging existing human clinical data to support new regulatory filings with the U.S. FDA, Health Canada and the European Medicines Agency (EMEA).
  • Advancing our products into orphan drug indications where patients are failing modern biologic or targeted therapy in order to obtain a guarantee of market exclusivity, attractive reimbursement, and high-likelihood of accelerated product approvals.
  • Establishing new intellectual property around our product candidates, including use, manufacturing, chemical composition and mechanism patent claims.
  • Obtaining commercial drug product from existing commercial manufacturers to accelerate entry into human clinical trials and reduce development costs.
  • Investigating the molecular mechanism of our drug candidates in order to establish additional patent claims and also to identify patients most likely to benefit from therapy (personalized medicine approach).
  • Commercializing our products through a combination of direct marketing and collaborative partnerships. For example, we target marketing our products to the small number of leading cancer centers in North America who specialize in the treatment of resistant orphan cancers and establishing sales and marketing partnerships for "large volume" tumor markets and in international markets including Europe & Asia.
  • Generating near-term revenue by leveraging opportunities in markets where our drug candidates are already approved or can be readily registered.
  • Operating on a "virtual" basis to minimize fixed-research costs while maintaining access to a highly-experienced and skilled workforce.


Product Development Programs: VAL-083

Del Mar Pharma's first product candidate, VAL-083, benefits from an historical investment of more than US$50 million by the National Cancer Institute (NCI) in the United States. The drug is well-characterized and has been studied in more than 40 Phase I & Phase II NCI-sponsored human clinical trials in the United States and in Europe. VAL-083 is approved as a cancer chemotherapeutic in China for the treatment of chronic myelogenous leukemia and solid tumors, including lung cancer.

 

http://www.delmarpharma.com/DelMarPharma_Presentation_Jan2013.pdf

 

KTRA
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
KTRA News: Kintara Reports Topline Results From Phase 2 Clinical Trial of VAL-083 for Recurrent GBM 07/01/2021 08:00:00 AM
KTRA News: Current Report Filing (8-k) 06/28/2021 06:02:07 AM
KTRA News: Kintara Therapeutics Set to Join Russell Microcap® Index 06/07/2021 08:00:00 AM
KTRA News: Kintara Therapeutics Enrolls Final Patient in Phase 2 Clinical Trial of VAL-083 for Adjuvant Treatment of Brain Tumors 06/03/2021 08:00:00 AM
KTRA News: Kintara Therapeutics to Present at the LD Micro Virtual Invitational Conference on June 9, 2021 06/02/2021 08:00:00 AM
PostSubject
#632   these shorts are relentless in killing every pop kiisko 07/07/21 03:42:21 PM
#631   Looks like a typical buy the rumor, sell blackcat 07/01/21 04:05:15 PM
#630   Crazy how they drop the price on good news! Paulness 07/01/21 02:21:23 PM
#629   With those results, they will be moving on blackcat 07/01/21 09:46:23 AM
#628   NEWS -- Kintara Reports Topline Results From Phase Paulness 07/01/21 08:51:13 AM
#627   I don't. They have not provided a potential blackcat 07/01/21 12:02:19 AM
#626   most probably dont. dont blame em. but i kiisko 06/30/21 11:01:00 PM
#625   do you know when phase 3 might start ? kiisko 06/30/21 10:59:56 PM
#624   Agreed. They have a potentially viable product in VAL-083. blackcat 06/30/21 05:59:43 PM
#623   thats comming out soon. but i was expecting kiisko 06/30/21 05:34:52 PM
#622   It won't get any attention until there are blackcat 06/28/21 09:48:59 PM
#621   Probably nobody believes it? snoopycomic 06/28/21 09:07:18 PM
#620   This thing can get to $30 super easy kiisko 06/28/21 02:55:48 PM
#619   NEWS -- Kintara Therapeutics Set to Join Russell Paulness 06/07/21 09:12:03 AM
#618   NEWS -- Kintara Therapeutics Enrolls Final Patient in Paulness 06/03/21 09:31:32 AM
#617   NEWS -- Kintara Therapeutics to Present at the Paulness 06/02/21 09:24:58 AM
#616   * * $KTRA Video Chart 05-26-2021 * * ClayTrader 05/26/21 05:34:34 PM
#615   NEWS -- Kintara Therapeutics Provides Positive Site Activation Paulness 05/26/21 08:57:46 AM
#614   NEWS -- Kintara Therapeutics Announces Fiscal Third Quarter Paulness 05/14/21 08:47:48 AM
#613   NEWS -- Kintara Therapeutics, Inc.: Invitation to the Paulness 05/11/21 07:15:55 AM
#612   NEWS -- Kintara Therapeutics to Participate at the Paulness 05/05/21 09:01:11 AM
#611   NEWS -- Kintara Therapeutics Appoints Tamara A. Seymour Paulness 05/04/21 08:10:42 AM
#610   NEWS -- Kintara Presents Updates on Two Phase Paulness 04/12/21 08:31:48 AM
#609   New data from AACR posted ! kiisko 04/10/21 10:41:35 PM
#608   PT is 2x current price, why isnt this raspberrymona 03/25/21 08:47:13 PM
#607   $KTRA still under the radar for now kiisko 03/21/21 11:55:56 PM
#606   $KTRA keeps getting shorted. Anyone have a time kiisko 03/17/21 03:42:37 PM
#605   NEWS -- Kintara Therapeutics to Participate in Benzinga Paulness 03/17/21 08:27:32 AM
#604   NEWS -- Kintara Therapeutics to Participate in Maxim Paulness 03/10/21 08:30:01 AM
#603   NEWS -- Kintara Therapeutics Appoints Dr. Mario Lacouture Paulness 03/03/21 08:45:59 AM
#602   NEWS -- Kintara Therapeutics to Present at the Paulness 03/02/21 08:11:40 AM
#601   NEWS -- Kintara Therapeutics Enrolls Final Patient in Paulness 02/17/21 08:14:25 AM
#600   NEWS -- Kintara Therapeutics Announces Fiscal Second Quarter Paulness 02/12/21 09:20:03 AM
#599   Nice https://finance.yahoo.com/news/ktra-potential-market-mgmt-methylated-102500 DayTraderOG 02/10/21 11:44:55 PM
#598   $2.40 very nice wesley_ 01/26/21 10:29:29 AM
#597   https://www.proactiveinvestors.com/companies/news/939187/dawson-james-issues-buy stockguard 01/21/21 08:55:26 PM
#596   Just starting to accumulate a position here as stockguard 01/21/21 06:09:31 PM
#595   $1.75 nice wesley_ 01/19/21 12:30:53 PM
#594   NEWS -- Kintara Announces Initiation of Patient Recruitment Paulness 01/13/21 08:14:24 AM
#593   Looking good on news today. GLTA quito_yume 01/13/21 08:11:36 AM
#592   NEWS -- Global Coalition for Adaptive Research, Kazia, Paulness 01/07/21 11:37:50 AM
#591   NEWS -- Kintara Therapeutics to Present at the Paulness 01/05/21 09:30:38 AM
#590   NEWS -- Kintara Therapeutics to Present at the Paulness 12/03/20 09:00:52 AM
#589   NEWS -- Kintara Therapeutics Reports 10 Months Progression-Free Paulness 11/19/20 08:16:37 AM
#588   NEWS -- Kintara and the Global Coalition for Paulness 10/21/20 08:29:06 AM
#587   After originally finding DMPI a couple of months Uranium 09/30/20 01:18:17 PM
#586   NEWS -- Kintara Therapeutics Announces Fiscal Year 2020 Paulness 09/21/20 08:53:06 AM
#585   NEWS -- Kintara Therapeutics Completes Final Closing of Paulness 09/01/20 08:47:05 AM
#584   NEWS -- Kintara Therapeutics (formerly DelMar Pharmaceuticals) to Paulness 08/26/20 08:54:29 AM
#583   NEWS -- Kintara Therapeutics Announces Closing of Additional Paulness 08/25/20 09:12:40 AM
PostSubject
Consent Preferences